These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 12154207

  • 1. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
    Scott DL, Strand V.
    Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
    [Abstract] [Full Text] [Related]

  • 2. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
    Golicki D, Newada M, Lis J, Pol K, Hermanowski T, Tłustochowicz M.
    Pol Arch Med Wewn; 2012 Mar; 122(1-2):22-32. PubMed ID: 22353705
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R, European Leflunomide Study Group.
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B.
    Arthritis Res Ther; 2019 Nov 15; 21(1):243. PubMed ID: 31730497
    [Abstract] [Full Text] [Related]

  • 11. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM.
    Clin Ther; 1999 Nov 15; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [Abstract] [Full Text] [Related]

  • 12. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I.
    Arch Intern Med; 1999 Nov 22; 159(21):2542-50. PubMed ID: 10573044
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D.
    Arthritis Rheum; 2003 Mar 22; 48(3):625-30. PubMed ID: 12632413
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis.
    Smolen JS.
    Scand J Rheumatol Suppl; 1999 Mar 22; 112():15-21. PubMed ID: 10668523
    [Abstract] [Full Text] [Related]

  • 17. A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P.
    Rheumatology (Oxford); 2003 Feb 22; 42(2):244-57. PubMed ID: 12595618
    [Abstract] [Full Text] [Related]

  • 18. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
    Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM.
    Ann Intern Med; 2002 Nov 05; 137(9):726-33. PubMed ID: 12416946
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan 05; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 20. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep 05; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.